Literature DB >> 32774220

Ductal Carcinoma in situ after Core Needle Biopsy: In Which Cases Is a Sentinel Node Biopsy Necessary?

Robbert J H van Leeuwen1, Birgitta Kortmann1, Herman Rijna1.   

Abstract

INTRODUCTION: In some hospitals it is still common practice to carry out a sentinel node biopsy (SNB) if ductal carcinoma in situ (DCIS) is determined in preoperative staging, although this is against international guidelines. The reason for this is because an infiltrative component can be demonstrated frequently in the final pathohistological examination. In this study, we wanted to investigate possible predictors for infiltrative growth, to select patients to do an SNB or to omit it.
MATERIAL AND METHODS: All patients with DCIS in the core needle biopsy (CNB), who were treated with surgery including an SNB, were included in a prospective data registry. Patient characteristics were collected through physical examination, mammography and ultrasonography. All characteristics of the DCIS were noted. After surgery, the pathological results were collected.
RESULTS: From the 287 patients, 39 (13.6%) had an infiltrative component in the definitive pathological examination despite only DCIS in preoperative CNB. In total, there were only 14 (4.9%) positive SNBs, of which 11 patients had infiltrative growth in the breast tumor and 3 (1.2% of patients with DCIS alone in the final pathology) did not. In addition, characteristics of the CNB, including microcalcifications and comedonecrosis, did not show a statistically significant higher risk for infiltration. DISCUSSION: Considering the low rates of positive SNBs in our population, we think that an SNB should not be performed in advance when DCIS is diagnosed, because if infiltrative growth is found in the final biopsy, an SNB could always be performed afterwards. Only if an SNB cannot be performed afterwards is an SNB indicated.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  Ductal carcinoma in situ; Invasive breast cancer; Sentinel node biopsy

Year:  2019        PMID: 32774220      PMCID: PMC7383287          DOI: 10.1159/000502277

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  32 in total

1.  A model to predict upstaging to invasive carcinoma in patients preoperatively diagnosed with ductal carcinoma in situ of the breast.

Authors:  Takafumi Kondo; Naoki Hayashi; Sachiko Ohde; Koyu Suzuki; Atsushi Yoshida; Hiroshi Yagata; Naoki Niikura; Takayuki Iwamoto; Kumiko Kida; Michiko Murai; Yuko Takahashi; Hiroko Tsunoda; Seigo Nakamura; Hideko Yamauchi
Journal:  J Surg Oncol       Date:  2015-09-08       Impact factor: 3.454

2.  Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer.

Authors:  Meagan E Brennan; Robin M Turner; Stefano Ciatto; M Luke Marinovich; James R French; Petra Macaskill; Nehmat Houssami
Journal:  Radiology       Date:  2011-04-14       Impact factor: 11.105

3.  Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ?

Authors:  Ashleigh M Francis; Christine E Haugen; Lynn M Grimes; Jaime R Crow; Min Yi; Elizabeth A Mittendorf; Isabelle Bedrosian; Abigail S Caudle; Gildy V Babiera; Savitri Krishnamurthy; Henry M Kuerer; Kelly K Hunt
Journal:  Ann Surg Oncol       Date:  2015-04-24       Impact factor: 5.344

4.  Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.

Authors:  Anthony Lucci; Linda Mackie McCall; Peter D Beitsch; Patrick W Whitworth; Douglas S Reintgen; Peter W Blumencranz; A Marilyn Leitch; Sukumal Saha; Kelly K Hunt; Armando E Giuliano
Journal:  J Clin Oncol       Date:  2007-05-07       Impact factor: 44.544

5.  Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ.

Authors:  Francisco J Dominguez; Mehra Golshan; Dalliah M Black; Kevin S Hughes; Michele A Gadd; Roger Christian; Beth-Ann Lesnikoski; Michelle Specht; James Michaelson; Barbara L Smith
Journal:  Ann Surg Oncol       Date:  2007-09-22       Impact factor: 5.344

6.  Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial.

Authors:  Lee Gravatt Wilke; Linda M McCall; Katherine E Posther; Pat W Whitworth; Douglas S Reintgen; A Marilyn Leitch; Sheryl G A Gabram; Anthony Lucci; Charles E Cox; Kelly K Hunt; James E Herndon; Armando E Giuliano
Journal:  Ann Surg Oncol       Date:  2006-03-02       Impact factor: 5.344

7.  Stereotactic vacuum-assisted breast biopsy in 2874 patients: a multicenter study.

Authors:  Ute Kettritz; Kerstin Rotter; Ingrid Schreer; Margarete Murauer; Rüdiger Schulz-Wendtland; Daniela Peter; Sylvia H Heywang-Köbrunner
Journal:  Cancer       Date:  2004-01-15       Impact factor: 6.860

8.  Recent trends in breast cancer among younger women in the United States.

Authors:  Louise A Brinton; Mark E Sherman; J Daniel Carreon; William F Anderson
Journal:  J Natl Cancer Inst       Date:  2008-11-11       Impact factor: 13.506

9.  Role of axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast.

Authors:  Giorgio Zavagno; Paolo Carcoforo; Renato Marconato; Zeno Franchini; Giuliano Scalco; Paolo Burelli; Paolo Pietrarota; Mario Lise; Roberto Mencarelli; Giovanni Capitanio; Andrea Ballarin; Maria Elena Pierobon; Giorgia Marconato; Donato Nitti
Journal:  BMC Cancer       Date:  2005-03-11       Impact factor: 4.430

10.  Borderline breast core needle histology: predictive values for malignancy in lesions of uncertain malignant potential (B3).

Authors:  N Houssami; S Ciatto; M Bilous; V Vezzosi; S Bianchi
Journal:  Br J Cancer       Date:  2007-04-23       Impact factor: 7.640

View more
  1 in total

1.  Necessity of sentinel lymph node biopsy in ductal carcinoma in situ patients: a retrospective analysis.

Authors:  Young Duck Shin; Hyung-Min Lee; Young Jin Choi
Journal:  BMC Surg       Date:  2021-03-22       Impact factor: 2.102

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.